Respiratory Biologics Depemokimab Depemokimab Demonstrates Sustained Long-Term Efficacy and Consistent Patient-Reported Outcomes Over 2 Years in Patients with Type 2 Asthma Irrespective of Baseline Inhaled Corticosteroid Dose: An Integrated Analysis of the Phase III SWIFT-1/-2 and the Open-Label Extension AGILE Studies Reynold A. Panettieri Poster Discussion — Presentation #519 — Session B22 Depemokimab Demonstrates Sustained Long-Term Efficacy and Consistent Patient-Reported Outcomes Over 2 Years in Patients with Type 2 Asthma and Chronic Rhinosinusitis with Nasal Polyps: An Integrated Analysis of the Phase III SWIFT-1/-2 and the Open Label Extension AGILE Studies Ian D. Pavord Poster Discussion — Presentation #520 — Session B22 Twice-Yearly Depemokimab Is Well Tolerated Over 2 Years in Patients with Type 2 Asthma: An Integrated Safety Analysis of the Phase III SWIFT-1/-2 and the Open-Label Extension AGILE Studies Arnaud Bourdin Thematic Poster — Presentation #P1391 — Session B32 Depemokimab Demonstrates Sustained Long-Term Efficacy and Consistent Patient-Reported Outcomes Over 2 Years in Patients with Type 2 Asthma: An Integrated Analysis of the SWIFT-1/-2 and AGILE Studies Ian D. Pavord Thematic Poster — Presentation #P1396 — Session B32 Blood Eosinophil Counts Are Positively Correlated with Type 2 Cytokine (IL-4, IL-5, and IL-13) Levels in Patients with Severe Asthma: Pooled Post Hoc Analysis of Data from SWIFT-1/-2 Studies Geoffrey Chupp Thematic Poster — Presentation #P1404 — Session A32 Patients in the US with Moderate to Severe Asthma and/or CRSwNP Prefer 6-Monthly Biologic Dosing Compared to More Frequent Biologic Dosing Schemes Arijita Deb Thematic Poster — Presentation #P1424 — Session B32 Efficacy and Safety of Twice-Yearly Depemokimab in Adolescent Patients with Asthma: Subgroup Analysis of the SWIFT-1/-2 Studies Daniel J. Jackson Thematic Poster — Presentation #P1388 — Session B32 When Patients Stay, Outcomes Improve: Real-World Evidence from Multiple Asthma Biologic Studies Justin Kwiatek Thematic Poster — Presentation #P1411 — Session B32 Who Receives Biologics? Comparative Real-World Insights into Biologic Access and Adherence in Severe Asthma in the USA Justin Kwiatek Oral Presentation — Session C14 Depemokimab vs Mepolizumab: Immuno-PET Imaging to Evaluate the Impact of YTE Modification on Tissue Distribution in Cynomolgus Monkeys Hasan Alsaid Thematic Poster — Presentation #P386 — Session C70 Variation of Clinical Characteristics and Disease Burden in Subgroups of Patients with Eosinophilic Granulomatosis With Polyangiitis (EGPA) Tham T. Le Poster Discussion — Presentation #411 — Session D23 Mepolizumab Disease Stability Is Achievable in a Wide Spectrum of Patients with Chronic Obstructive Pulmonary Disease Receiving Mepolizumab: Pooled Results from Phase III Randomized Controlled Trials Dave Singh Thematic Poster — Presentation #P1506 — Session A34 Mepolizumab Reduces the Burden of Chronic Obstructive Pulmonary Disease Exacerbations in a Wide Spectrum of Patients: Pooled Results from Phase III Randomized Controlled Trials Gerard J. Criner Thematic Poster — Presentation #P1496 — Session A34 Mepolizumab Is Associated with Reductions in Exacerbations and Oral Corticosteroid Use in a Real-World Setting Among US Patients with Chronic Obstructive Pulmonary Disease Sunay Shah Thematic Poster — Presentation #P1504 — Session A34 Mepolizumab Is Associated with Reductions in Healthcare Resource Utilization in a Real-World Setting Among US Patients with Chronic Obstructive Pulmonary Disease Rosirene Paczkowski Thematic Poster — Presentation #P1505 — Session A34 Mepolizumab Reduces Type-2 COPD Exacerbations Requiring Systemic Corticosteroids in a Wide Spectrum of Patients: Pooled Results from Phase III Randomized Controlled Trials Nicola Hanania Thematic Poster — Presentation #P1430 — Session B32 Patients with Chronic Obstructive Pulmonary Disease with Exacerbations and Triple Therapy Linked to Increased Clinical and Economic Burden: US Database Claims Analysis David Mannino Thematic Poster — Presentation #P1515 — Session A34 Mepolizumab in Severe Asthma With and Without Comorbid Chronic Rhinosinusitis with Nasal Polyps: Long‑Term Real‑World Evidence from the TYREX Study Luis Alejandro Pérez de Llano Thematic Poster — Presentation #P47 — Session C33 Impact of Baseline Eosinophil Thresholds on Long-Term Outcomes in Severe Asthma Patients Receiving Mepolizumab: A Retrospective Multicenter Analysis Luis Alejandro Pérez de Llano Thematic Poster — Presentation #P48 — Session C33 Inhaled Therapeutics Salbutamol MDI  Developing Low-Carbon Salbutamol MDI: Assessment of Safety and Tolerability of Salbutamol with Propellant HFA-152a Maximilian Plank Thematic Poster — Presentation #P1394 — Session A32 Patient Insights on Experience With Metered-Dose Inhalers Using Novel Low-Carbon Propellant HFA-152a Compared With the Current Propellant HFA-134a Ruth Tal-Singer Thematic Poster — Presentation #P1424 — Session A32 Fluticasone Furoate, Umeclidinium & Vilanterol  Effectiveness of Once‑Daily Single-Inhaler Triple Therapy Versus Dual Bronchodilator Therapy in Patients with Mild‑to‑Moderate COPD in Japan (TRACK Study)* Koichiro Takahashi Thematic Poster — Presentation #P1488 — Session A34 Impact of Immediate Diagnosis and Treatment on Recovery from COPD Exacerbations During Pulmonary Rehabilitation* Rainer Gloeckl Oral Presentation — Session C97 Improved Clinical Outcomes and Achievability of Clinical Remission After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma in the United States Rosirene Paczkowski Thematic Poster — Presentation #P988 — Session B40 Defining Disease Stability in COPD: A Post Hoc Analysis of the Phase III IMPACT Trial MeiLan K. Han Oral Presentation — Session A16 Refractory Chronic Cough Camlipixant Prevalence of Refractory Chronic Cough and Unexplained Chronic Cough in Older Adults (≥65 Years) Based on a Claims Algorithm Using Medicare Fee-for-Service Administrative Claims Data Krishna Sundar Thematic Poster — Presentation #P71 — Session B39 Chart Review of Real-World Characteristics and Treatment Patterns of Patients with Refractory or Unexplained Chronic Cough in the United States Michael Ghobrial Thematic Poster — Presentation #P72 — Session B39 Clinical Characteristics, Disease Burden, and Treatments in Adult Patients with Refractory Chronic Cough/Unexplained Chronic Cough: A Systematic Literature Review Julie Rouette Thematic Poster — Presentation #P1043 — Session B58 Respiratory Portfolio Predictive Validity of Three Definitions of Chronic Bronchitis (MRC, SGRQ, and CAT) in COPD Fengyan Wang Poster Discussion — Presentation #507 — Session B102 Mucus Plugging, Air Trapping and Emphysema in Healthy Young Adult Never-Smokers, Young Adult Smokers with Preserved Lung Function, and COPD Patients* Aaron Braddy-Green Poster Discussion — Presentation #818 — Session D30 Acute Respiratory Events in Symptomatic Smokers Are Associated with Accelerated Lung Function Decline in the British Early COPD Network (BEACON) Cohort* Andrew I. Ritchie Poster Discussion — Presentation #801 — Session D30 Lobar Mucus Plugging Identifies Regions of Air Trapping in Smokers with Preserved Lung Function (BEACON) and COPD* Aaron Braddy-Green Oral Presentation — Session D96 Pipeline Targeted Literature Review of Idiopathic Pulmonary Fibrosis (IPF) Epidemiology and Antifibrotic Treatment Discontinuation Philip L. Molyneaux Poster Discussion — Presentation #512 — Session C103